Index

Abortion, missed, antifibrinolytic therapy in, 57
Acrosin, inhibition by fibrinolytic inhibitors for contraception, 78
Aminocaproic acid. See Epsilon-aminocaproic acid
Aminocarboxylic acids, 78
—, mode of action of, 36
Angioneurotic oedema, hereditary and non-hereditary, antifibrinolytic therapy in, 77
Antifibrinolytic therapy, basis of, 35
—, future prospects for, 77
— in gastrointestinal haemorrhage, clinical trials of, 66
— in gastrointestinal tract surgery, 60
— in gynaecology, 55
— in haemophilia, 50
α2-Antiplasmin, 1, 24
—, and regulation of fibrinolysis, 25
—, assay with chromogenic substrates, 48
—, congenital deficiency of, 3
Aprotinin, 36, 79
—, mode of action of, 37
Astedt, B.: Adjuvant treatment of ovarian carcinoma with tranexamic acid, 74
Benzoipiperidine derivative, new, inhibiting thrombin, 79
Bleeding due to excessive fibrinolysis, classification of, 37
—, fibrinolytic, local, EACA and AMCA in, 45
—, —, —, within organs, 39
— in pregnancy, antifibrinolytic therapy in, 57
—, postpartum, secondary, antifibrinolytic therapy in, 57
— problems, endothelial plasminogen activator in, 19
— See also Gastrointestinal haemorrhage; Menstrual bleeding
Blood activator of plasminogen, 21
—, gastric, fibrinolytic activity in, 63
—, plasmin inhibitors in, 24
—, plasminogen inhibitors in, 27
Bonnar, J., Guillebaud, J., Kasonde, J. M., and Sheppard, B. L.: Clinical applications of fibrinolytic inhibition in gynaecology, 55
Cadaveric activator of plasminogen, 21
Carcinoma, ovarian, adjuvant treatment with tranexamic acid, 74
Caseinolysis, effect of EACA, 36
Chromogenic substrates in assessment of plasmin inhibitors, 48
Coagulation disorders, hereditary, 39
Coagulation-fibrinolysis balance, hypothesis of, 2
Collet, D.: Natural inhibitors of fibrinolysis, 24
Complement activation in SLE, blocking by plasmin inhibitors, 77
Contraception by inhibition of acrosin with antifibrinolytic inhibitors, 78
Davidson, J. F., and Walker, I. D.: Biological role of fibrinolysis, 1
Dental extractions in haemophilia, antifibrinolytic therapy for, 52
Endothelial activator of plasminogen, 18
Epsilon-aminocaproic acid, 36
—, clinical pharmacology of, 41
—, effect on caseinolysis, 36
—, on fibrinolysis, 37
— in gynaecological tract surgery, 60
—, pharmacokinetics of, 41, 50
—, toxicity of, 44, 50, 58
Fibrin and fibrinogen breakdown products, molecular mechanisms and clinical implications, 10
—, breakdown products, practical implications of, 14
—, cross-linked, 12
—, exogenous, lysis of, prevention by fibrinolytic inhibitors, 78
—, formation in intravascular coagulation-fibrinolysis syndrome, 31
—, non-cross-linked, 11
—, role in fibrinolysis, 1
Fibrin-plasmin breakdown products, 10
—, interactions, 11
Fibrinogen fragmentation mechanisms, 10
Fibrinolysis, activation of, 2
— and gastrointestinal haemorrhage, 63
— and menstruation, 55
—, biological role of, 1
—, congenital abnormalities of, 3
—, effect of EACA, 37
—, excessive, haemorrhage due to, classification of, 37
—, secondary to DIC, 38
— in intravascular coagulation-fibrinolysis syndrome, 32
—, inhibition of, physiopathological conditions associated with, 27
—, inhibitors of, in treatment. See Antifibrinolytic therapy
—, molecular interactions in, 1
—, natural inhibitors of, 24
—, primary, 38
—, regulation of, and α2-antiplasmin, 25
—, synthetic inhibitors of, 78
—, —, —, —, clinical effects of, 27
—, —, —, —, mode of action of, 35
—, systemic, EACA and AMCA in, 45
—, therapeutic possibilities in, 3
Fibrinolysis-coagulation balance, hypothesis of, 2
Fibrinolytic activity in gastric blood, 63
—, —, —, —, tissue and juice, 64
Fosstad, H.: Tranexamic acid (AMCA) in aneurysmal subarachnoid haemorrhage, 68
Gaffney, P. J.: Breakdown products of fibrin and fibrinogen: molecular mechanisms and clinical implications, 10
Gastric blood, fibrinolytic activity in, 63
— tissue and juice, fibrinolytic activity in, 64
Gastrointestinal haemorrhage and fibrinolysis, 63
—, antifibrinolytic therapy in, clinical trials of, 66
Genitourinary tract surgery, antifibrinolytic therapy in, 60
Glycosaminoglycan polysulphates of bovine origin, 79
Gynaecology, antifibrinolytic therapy in, 55
Haematuria, antifibrinolytic therapy in, 51
—, EACA and AMCA in, 45
Haemophilia, antifibrinolytic prophylaxis in, 51
—, therapy in, 50
—, —, —, during surgery, 52
—, for dental extractions, 52
Haemorrhage, subarachnoid, aneurysmal, tranexamic acid in, clinical trials of, 68
—, See also Bleeding
Hyperplasminaeia, 38
Inflammation, endothelial plasminogen activator in, 20
Intrauterine devices, menstrual bleeding and fibrinolysis with, 56
Intravenous coagulation, disseminated, excessive fibrinolysis secondary to, 38
—, coagulation-fibrinolysis syndrome, clinical aspects of, 32
—, —, pathophysiology of, 31
—, —, treatment of, 33
Lalatta, Z. S.: Assessment of inhibitors with chromogenic substrates, 48
Lupus erythematosus, systemic, blocking of complement activation by plasmin inhibitors in, 77
Lysine-binding sites, 5
α2-Macroglobulin, 25
—, assay with chromogenic substrates, 48
Malignancy, gynaecological, antifibrinolytic therapy in, 57
Menstrual bleeding, excessive, and fibrinolysis, with intrauterine devices, 36
—, —, antifibrinolytic therapy in, 55
Menstruation and fibrinolysis, 55
Myocardial infarction, endothelial plasminogen activator in, 19
Neutrophil proteases, inhibition by fibrinolytic inhibitors, 77
Nilsson, I. M.: Clinical pharmacology of aminocaproic and tranexamic acids, 41
Oedema, angioneurotic, hereditary and non-hereditary, antifibrinolytic therapy in, 77
OGSTON, D.: Biochemistry of the plasmin system, 5
Ovarian carcinoma, adjuvant treatment with tranexamic acid, 74

Plasma protease inhibitors, 24, 25
Plasmin, biochemistry of, 7
——, formation from plasminogen, 1, 6
—— inhibitors, assessment with chromogenic substrates, 48
—— —— in blood, 24
—— —— in platelets, 26
—— system, biochemistry of, 5
Plasmin-fibrin breakdown products, 10
—— interactions, 11
Plasminogen activators, 1, 60
—— ——, classification of, 18
—— —— in menstruation, 55
—— ——, morphological aspects of, 18
——, biochemistry of, 5
——, conversion to plasmin, 1, 6
—— inhibitors in blood, 26
—— —— in platelets, 27
—— tissue activator activity, gastric, 64
—— ——, tumour activator, 74
Platelets, plasmin inhibitors in, 26
——, plasminogen inhibitors in, 27
POLLER, L.: Fibrinolysis and gastrointestinal haemorrhage, 63
Pregnancy, bleeding in, antifibrinolytic therapy in, 57
PRENTICE, C. R. M.: Basis of antifibrinolytic therapy, 35
RIZZA, C. R.: Inhibitors of fibrinolysis in the treatment of haemophilia, 50

SHARP, A. A.: Pathophysiology of intravascular coagulation and fibrinolysis, 31
SHEPPARD, B. L. See BONNAR, J., GUillebaud, J., et al.
Shock lung, endothelial plasminogen activator in, 19
Subarachnoid haemorrhage, aneurysmal, tranexamic acid in, clinical trials of, 68

Thrombin, new benzopiperidine derivative inhibiting, 79
Thrombolysis, mechanism of, 7
Tissue plasminogen activator activity, gastric, 64
TODD, A. S.: Plasminogen activators: a morphologist's view, 18
Tranexamic acid, 36
—— ——, clinical pharmacology of, 41
—— —— in adjuvant treatment of ovarian carcinoma, 74
—— —— in aneurysmal subarachnoid haemorrhage, clinical trials of, 68
—— —— in genitourinary tract surgery, 60
—— ——, pharmacokinetics of, 42, 50
—— ——, toxicology of, 44, 50, 58
Tripeptide aldehyde analogues, 79
Tumour-plasminogen activator, 74

Urinary tract, tissue plasminogen activator in, 20
Urokinase, 22

VERSTRAETE, M.: Future prospects for use of fibrinolysis inhibitors, 77

WALKER, I. D. See DAVIDSON, J. F., and WALKER, I. D.